<a href="https://laohu8.com/S/ALXO">ALX Oncology Holdings</a> Inc. Announces Launch of Phase 1 Trial for ALX2004 in EGFR-Expressing Solid Tumors, First Patient Dosing Expected This Month
ALX Oncology Holdings Inc., a clinical-stage biotechnology company, has announced upcoming clinical milestones for its pipeline of novel cancer therapies. The ASPEN-Breast Cancer trial is set to begin patient dosing in the fourth quarter of 2025, with interim data expected in the third quarter of 2026. Additionally, the ALX2004 Phase 1 trial for EGFR-expressing solid tumors will commence patient dosing in August 2025, and initial safety data is anticipated in the first half of 2026. In the ASPEN-06 trial, data has highlighted CD47 expression as a key predictive biomarker for response to evorpacept in HER2+ Gastric Cancer, with updated findings to be presented at a medical conference in the fourth quarter of 2025. The company is focused on achieving these and other data milestones within its cash runway, extended into the first quarter of 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-107277), on August 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.